Planning for Competition With MMIT's Strategic Launch Report

This page describes how a biopharma company used MMIT's Strategic Launch Report and analog drugs to inform its risk-mitigation strategy ahead of a competitor's market entry. Stated benefits: creating "an accurate commercial forecast for your brand," getting insights to "inform your business planning cycle," and validating "market assumptions" to "create risk mitigation plans for a variety of scenarios." It is primarily a landing page with a downloadable PDF; no specific numerical outcomes appear in the visible text.

The customer is anonymised in Norstella’s own case study — not withheld by us.

Norstella is a holding company merging several pharma-intelligence brands — Citeline (trial intelligence), Evaluate (forecasting), MMIT (payer/formulary data) and Panalgo (real-world analytics) — into one data asset.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.